TY - JOUR T1 - Is therapeutic inertia present in primary diabetes care in Malaysia? A prospective study JF - medRxiv DO - 10.1101/19002584 SP - 19002584 AU - Boon-How Chew AU - Husni Hussain AU - Ziti Akthar Supian Y1 - 2019/01/01 UR - http://medrxiv.org/content/early/2019/07/19/19002584.abstract N2 - Aims This prospective study aimed to determine the proportions of therapeutic inertia when treatment targets not achieved in adults T2D at three public health clinics in Malaysia.Methods The index prescriptions were those when the annual blood tests were reviewed. Prescriptions were verified and classified as 1) no change, 2) stepping up and 3) stepping down. Multivariable logistic regression and sensitive analyses were conducted.Results At follow-up, 552 participants were available for the assessment of therapeutic inertia (78.9% response rate). The mean (SD) age and diabetes duration were 60.0 (9.9) years and 5.0 (6.0) years, respectively. High therapeutic inertia were observed in oral anti-diabetic (61-72%), anti-hypertensive (34-65%) and lipid-lowering therapies (56-77%), and lesser in insulin (34- 52%). Insulin therapeutic inertia was more likely among those with shorter diabetes duration (adjusted OR 0.9, 95% CI 0.87, 0.98). Those who did not achieve treatment targets were less likely to experience therapeutic inertia: HbA1c ≥ 7.0%: adjusted OR 0.10 (0.04, 0.24); BP ≥ 140/90 mmHg: 0.28 (0.16, 0.50); LDL-cholesterol ≥ 2.6 mmol/L: 0.37 (0.22, 0.64).Conclusions Although therapeutic intensifications were more likely in the present of non- achieved treatment targets but the proportions of therapeutic inertia were high.Trial registration NCT02730754 https://clinicaltrials.gov/ct2/show/NCT02730754HighlightsProbably the first study in Malaysia or Asian countriesAssessing three main therapeutic inertia among T2D at primary diabetes careProportions of therapeutic inertia were highTherapeutic inertia was unlikely in non-achieved treatment targetsPossible causes of therapeutic inertia require identification and rectificationCompeting Interest StatementThe authors have declared no competing interest.Clinical TrialNCT02730754Funding StatementThis work was partly supported by the Ministry of Higher Education Malaysia (grant numbers KPT(BS)730928075371, 2013) and Universiti Putra Malaysia?s journal publication awards (award numbers UPM/TNCPI/RMC/5.1.17/F5(16)). The funding bodies had no role in the design of the study or in the collection, analysis, or interpretation of data or in writing the manuscript.Author DeclarationsAll relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesAny clinical trials involved have been registered with an ICMJE-approved registry such as ClinicalTrials.gov and the trial ID is included in the manuscript.YesI have followed all appropriate research reporting guidelines and uploaded the relevant Equator, ICMJE or other checklist(s) as supplementary files, if applicable.Not ApplicableData will be made available upon request. ER -